New diabetes drug tested in people with kidney issues

NCT ID NCT06370819

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study tested how different levels of kidney function affect the processing of a single dose of the experimental drug NNC0519-0130. Thirty-six adults with type 2 diabetes and varying kidney function (normal to severely impaired) received one injection. Researchers measured drug levels in the blood to see if kidney problems change how the drug is handled, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0519-0130
What this could lead to: If successful, this study could help determine the right dose of NNC0519-0130 for people with type 2 diabetes who also have kidney problems.
What could go wrong: This is an early, small study (36 participants) that only looks at drug levels in the blood, not at actual treatment effects or long-term safety. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Charité - Campus Charité Mitte - Charité Research Organisation GmbH

Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.